Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 5Gastrointestinal 5CNS 5Lymphoid 4Sarcoma 3Other solid neoplasm 2Gynecologic 2Dermatologic 2Breast 2Tumor-Agnostic 1Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Endocrine 1

Conditions

Pituitary Neoplasms 1Brain Neoplasms 1

Interventions

Everolimus 15Magnetic Resonance Spectroscopy 8lutetium Lu 177 dotatate 7pasireotide 5gallium Ga 68 dotatate 5Cisplatin 5Specimen Handling 4Positron Emission Tomography Computed Tomography 4Nivolumab 4Fluorodeoxyglucose F18 4Carboplatin 4Temozolomide 3Paclitaxel 3Octreotide 3Lutetium-177 3Ga(III)-DOTATOC 3Etoposide 3(177)Lu-DOTA-EB-TATE 3vandetanib 2pembrolizumab 2olaparib 2fluorodopa F 18 2dabrafenib 2copper dotatate CU-64 2cemiplimab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Trastuzumab 2Radiotherapy 2Radiosurgery 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Blood Specimen Collection × Endocrine × Clear all
NCT03465618 2026-05-01

A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
17 enrolled
CNSEndocrine

Brain Neoplasms, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡